<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02320825</url>
  </required_header>
  <id_info>
    <org_study_id>14-233</org_study_id>
    <nct_id>NCT02320825</nct_id>
  </id_info>
  <brief_title>Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases</brief_title>
  <official_title>Phase III Multicenter Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether giving one higher dose of radiation is as
      good at treating the tumor in the patient's spine after surgery as giving three lower doses
      of radiation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local tumor control using MRI or CT</measure>
    <time_frame>2 years</time_frame>
    <description>will be radiographically determined according to routine standard of care post-surgical and post-treatment imaging (MRI or CT) of the spine. Local tumor control will be defined as the lack of local tumor progression at the irradiated site on follow-up imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment-related toxicity using CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events will be assessed by the investigators according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life between the two cohorts determined through patient-reported responses of the BPI</measure>
    <time_frame>2 years</time_frame>
    <description>will be determined through patient-reported responses of the BPI. Pain severity at its worst (question #5) and the average of the pain interference (average of question #9)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Spinal Metastases</condition>
  <arm_group>
    <arm_group_label>single-fraction SRS (24 Gy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-fraction (24Gy) SRS within eight weeks of having undergone spinal decompression surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high-dose hypofractionated SRS (27 Gy in 3 fractions)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hypofractionated (3 fractions of 9Gy, total dose of 27Gy) SRS within eight weeks of having undergone spinal decompression surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>single-fraction SRS</intervention_name>
    <arm_group_label>single-fraction SRS (24 Gy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>high-dose hypofractionated SRS</intervention_name>
    <arm_group_label>high-dose hypofractionated SRS (27 Gy in 3 fractions)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality of Life Measures</intervention_name>
    <arm_group_label>single-fraction SRS (24 Gy)</arm_group_label>
    <arm_group_label>high-dose hypofractionated SRS (27 Gy in 3 fractions)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically diagnosed metastatic cancer (Diagnosis made or confirmed at MSKCC for
             MSKCC participants. Institutional pathologic determination accepted from participating
             multicenter sites.)

          -  Age ≥18 years

          -  Life expectancy ≥3 months

          -  ECOG ≤ 3

          -  Spinal surgery carried out with the goal of spinal cord decompression and spinal
             stabilization within 8 weeks

          -  Post-operative CT myelogram or MRI perfusion with evidence of separation of tumor and
             the spinal cord It should be noted that patients with multiple lesions will be
             eligible as long as there are no overlapping fields of radiation, including at various
             time frames.

        Exclusion Criteria:

          -  Primary spine tumor

          -  Age &lt; 18

          -  Pregnancy

          -  Lack of adequate (≥ 2 mm) separation between the spinal cord and the tumor on
             post-operative CT myelogram or MRI perfusion

          -  Radiosensitizing chemotherapy (taxol, taxotere, cisplatin, gemcitabine,
             5-fluorouracil) given within one week of radiation treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilya Laufer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2014</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic Radiosurgery (SRS)</keyword>
  <keyword>Single-Fraction</keyword>
  <keyword>Hypofractionated</keyword>
  <keyword>Spinal surgery</keyword>
  <keyword>14-233</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

